ArticleThe Lancet. Oncology2020
Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours.
Ulrik LassenPubMed ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this papercites it
ArticleThe Lancet. Oncology2020
Ulrik LassenPubMed ↗Publisher ↗
No numbers read from the abstract.